These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 8888955)

  • 1. Nuclear areas in breast cancer: relationship with estrogen and progesterone receptor expression.
    Maiorana A; Cavallari V; Bagni A; Ussia F; Maiorana MC; Fano RA
    Anal Cell Pathol; 1996 Aug; 11(3):199-209. PubMed ID: 8888955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
    Masiuk M
    Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
    Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
    Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
    Keshgegian AA
    Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
    Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
    Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry.
    van Agthoven T; Timmermans M; Foekens JA; Dorssers LC; Henzen-Logmans SC
    Am J Pathol; 1994 Jun; 144(6):1238-46. PubMed ID: 7515559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
    Thike AA; Chng MJ; Fook-Chong S; Tan PH
    Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
    Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
    Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of results of estrogen and progesterone receptor assays performed in a community hospital.
    Szakacs JG; Arroyo JG; Girgenti AJ
    Ann Clin Lab Sci; 1986; 16(4):266-73. PubMed ID: 3740795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors].
    Sundblad AS; Caprarulo L
    Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.
    Berger U; Wilson P; Thethi S; McClelland RA; Greene GL; Coombes RC
    Cancer Res; 1989 Sep; 49(18):5176-9. PubMed ID: 2766287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
    Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
    Kolár Z; Murray PG; Zapletalová J
    Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.